Company Description
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States.
Its product pipeline includes birtamimab, an investigational humanized antibody, which in phase 3 clinical trial to treat patients with AL amyloidosis; and Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson’s disease and other synucleinopathies.
The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer’s disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer’s disease; PRX123, a Dual Aβ-Tau Vaccine, which is in preclinical trial for treating Alzheimer’s disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases.
It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target α-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43.
Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
| Country | Ireland |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 163 |
| CEO | Gene Kinney |
Contact Details
Address: 77 Sir John Rogerson’s Quay, Block C Dublin, D02 VK60 Ireland | |
| Phone | 353 1 236 2500 |
| Website | prothena.com |
Stock Details
| Ticker Symbol | PRTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001559053 |
| CUSIP Number | G72800108 |
| ISIN Number | IE00B91XRN20 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gene G. Kinney Ph.D. | President, Chief Executive Officer and Director |
| Tran B. Nguyen M.B.A. | Chief Financial Officer and Chief Strategy Officer |
| Brandon S. Smith | Chief Operating Officer |
| Carol D. Karp | Chief Regulatory Officer |
| Karin L. Walker CPA | Chief Accounting Officer and Controller |
| Dr. Wagner M. Zago Ph.D. | Chief Scientific Officer |
| Mark C. Johnson C.F.A. | Vice President of Investor Relations |
| Michael J. Malecek | Chief Legal Officer and Company Secretary |
| David A. Ford | Chief People Officer |
| Dr. Chad J. Swanson Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2025 | ARS | Filing |
| Mar 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 28, 2025 | DEF 14A | Other definitive proxy statements |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 21, 2025 | SCHEDULE 13G/A | Filing |
| Feb 20, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 10, 2025 | SCHEDULE 13G/A | Filing |
| Jan 3, 2025 | SCHEDULE 13D/A | Filing |
| Dec 30, 2024 | 8-K | Current Report |